Palladium(II)-Diphosphine/Lapachol complexes: Structural Insights and Selective Activity against Cisplatin-Resistant Ovarian Cancer
- 1Federal University of São Carlos (UFSCar) , , , ,
- 2University of São Paulo (USP) , , , ,
- 3University of São Paulo , , , ,
Abstract
Here, we have developed and structurally characterized a series of palladium(II) complexes combining diphosphine ligands and the natural product lapachol (lap), namely [Pd(dppp)(lap)]PF6 (1), [Pd(dppb)(lap)]PF6 (2), and [Pd(dppf)(lap)]PF6 (3), where dppp = 1,3-bis(diphenylphosphino)propane, dppb = 1,4-bis(diphenylphosphino)butane, and dppf = 1,1′-bis(diphenylphosphino)ferrocene, to explore structure–activity relationships in anticancer systems. The complexes [Pd(dppp)(lap)]PF6 (1), [Pd(dppb)(lap)]PF6 (2), and [Pd(dppf)(lap)]PF6 (3) were synthesized and structurally characterized. X-ray diffraction confirmed O,O-chelation of lap and square-planar geometry around the Pd(II) center. Biological evaluation revealed that the activity of the complexes strongly depended on the diphosphine ligand. The ferrocenyl-containing complex 3 displayed remarkable cytotoxicity and selectivity toward ovarian cancer cells, particularly toward the cisplatin-resistant A2780cis line, outperforming cisplatin. Mechanistic studies demonstrated that complex 3 induced apoptosis in a concentration-dependent manner, as evidenced by morphological changes, inhibited colony formation, and cell cycle arrest in the sub-G1 phase, while activity in 3D tumor spheroid models was retained. On the basis of these results, complex 3 was effective under physiologically relevant conditions. DNA-binding experiments suggested that complexes 1–3 interacted with DNA weakly via groove binding rather than classical covalent mechanisms. Moderate to strong binding of the complexes to human serum albumin supported that they can potentially be transported in biological media. Overall, these findings highlight the critical role played by the diphosphine ligand in modulating the biological activity of the complexes and identify complex 3 as a promising candidate for developing new metallodrugs to target resistant tumors via mechanisms that differ from the mechanisms of platinum-based agents.
Related
- Remote and site-selective C–H functionalization of benzamides enabled by palladium 1,7-migration
- Descriptor-Based Regression Analysis Enables the Discovery of Highly Selective Ligands for Palladium-Catalyzed Siloxycyclopropanation
- Conformational control for selective CO2-to-isocyanate conversion in a series of dizinc macrocycle complexes
- Polyoxometalate-Assisted Crystallization: A General Strategy Enabling Structural Characterization of Molecular Radium Complexes
- Selective Ligand Replacement Leads to Carbene Complexes as Catalysts in Proteins
BibTeX
@article{dutra2026palladiumiidiphosphinelapachol,
title = {{Palladium(II)-Diphosphine/Lapachol complexes: Structural Insights and Selective Activity against Cisplatin-Resistant Ovarian Cancer}},
author = {Jocely Lucena Dutra and Tamara Teixeira and Isabella C. Prescilio and Josias S. Rocha and Carlos André F. Moraes and Marcia R. Cominetti and Fillipe V Rocha and Javier Ellena and João Honorato de Araujo-Neto and Alzir A. Batista},
journal = {ACS Omega},
year = {2026},
month = nov,
doi = {10.1021/acsomega.6c07113},
url = {https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c07113/5466185/Palladium-II-Diphosphine-Lapachol-complexes},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Palladium(II)-Diphosphine/Lapachol complexes: Structural Insights and Selective Activity against Cisplatin-Resistant Ovarian Cancer
AU - Jocely Lucena Dutra
AU - Tamara Teixeira
AU - Isabella C. Prescilio
AU - Josias S. Rocha
AU - Carlos André F. Moraes
AU - Marcia R. Cominetti
AU - Fillipe V Rocha
AU - Javier Ellena
AU - João Honorato de Araujo-Neto
AU - Alzir A. Batista
PY - 2026
DA - 2026/11/07
JO - ACS Omega
DO - 10.1021/acsomega.6c07113
UR - https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c07113/5466185/Palladium-II-Diphosphine-Lapachol-complexes
AB - Here, we have developed and structurally characterized a series of palladium(II) complexes combining diphosphine ligands and the natural product lapachol (lap), namely [Pd(dppp)(lap)]PF6 (1), [Pd(dppb)(lap)]PF6 (2), and [Pd(dppf)(lap)]PF6 (3), where dppp = 1,3-bis(diphenylphosphino)propane, dppb = 1,4-bis(diphenylphosphino)butane, and dppf = 1,1′-bis(diphenylphosphino)ferrocene, to explore structure–activity relationships in anticancer systems. The complexes [Pd(dppp)(lap)]PF6 (1), [Pd(dppb)(lap)]PF6 (2), and [Pd(dppf)(lap)]PF6 (3) were synthesized and structurally characterized. X-ray diffraction confirmed O,O-chelation of lap and square-planar geometry around the Pd(II) center. Biological evaluation revealed that the activity of the complexes strongly depended on the diphosphine ligand. The ferrocenyl-containing complex 3 displayed remarkable cytotoxicity and selectivity toward ovarian cancer cells, particularly toward the cisplatin-resistant A2780cis line, outperforming cisplatin. Mechanistic studies demonstrated that complex 3 induced apoptosis in a concentration-dependent manner, as evidenced by morphological changes, inhibited colony formation, and cell cycle arrest in the sub-G1 phase, while activity in 3D tumor spheroid models was retained. On the basis of these results, complex 3 was effective under physiologically relevant conditions. DNA-binding experiments suggested that complexes 1–3 interacted with DNA weakly via groove binding rather than classical covalent mechanisms. Moderate to strong binding of the complexes to human serum albumin supported that they can potentially be transported in biological media. Overall, these findings highlight the critical role played by the diphosphine ligand in modulating the biological activity of the complexes and identify complex 3 as a promising candidate for developing new metallodrugs to target resistant tumors via mechanisms that differ from the mechanisms of platinum-based agents.
SN - 2470-1343
ER -